公开(公告)号：WO2008002956A3

公开(公告)日：2008-07-03

申请号：PCT/US2007072185

申请日：2007-06-27

Applicant: ABBOTT LAB ,  FAGHIH RAMIN ,  GFESSER GREGORY A ,  LYNCH CHRISTOPHER L ,  GOPALAKRISHNAN MURALI ,  GOPALAKRISHNAN SUJATHA ,  MALYSZ JOHN ,  GUBBINS EARL J ,  EL KOUHEN RACHID ,  LI JINHE ,  SARRIS KATHY A ,  MICHMERHUIZEN MELISSA J ,  WANG YING

Inventor： FAGHIH RAMIN ,  GFESSER GREGORY A ,  LYNCH CHRISTOPHER L ,  GOPALAKRISHNAN MURALI ,  GOPALAKRISHNAN SUJATHA ,  MALYSZ JOHN ,  GUBBINS EARL J ,  EL KOUHEN RACHID ,  LI JINHE ,  SARRIS KATHY A ,  MICHMERHUIZEN MELISSA J ,  WANG YING

IPC: C07D417/04 ,  A61K31/422 ,  A61K31/427 ,  C07D413/04 ,  C07D417/14

CPC classification number: C07D417/04 ,  C07D413/04 ,  C07D417/14

Abstract: The invention relates to compounds of formula I selected from compounds. The compounds of formula (I) in treating conditions and disorders that are regulated by the nicotinic acetylcholine receptors.

Abstract translation: 本发明涉及选自化合物的式I化合物。 式（I）化合物在治疗由烟碱乙酰胆碱受体调节的病症和病症中。

公开(公告)号：MX2008016336A

公开(公告)日：2009-01-16

申请号：MX2008016336

申请日：2007-06-27

Applicant: ABBOTT LAB

Inventor： FAGHIH RAMIN ,  GFESSER GREGORY A ,  LYNCH CHRISTOPHER L ,  GOPALAKRISHNAN MURALI ,  GOPALAKRISHNAN SUJATHA ,  MALYSZ JOHN ,  GUBBINS EARL J ,  KOUHEN RACHID EL ,  LI JINHE ,  SARRIS KATHY A ,  MICHMERHUIZEN MELISSA J ,  WANG YING

IPC: C07D417/04 ,  A61K31/422 ,  A61K31/427 ,  C07D413/04 ,  C07D417/14

Abstract: La invención se refiere a una serie de derivados de tiazolina y oxazolina, composiciones de los mismos, y métodos para tratar condiciones y trastornos utilizando dichos compuestos.

公开(公告)号：CA2659762A1

公开(公告)日：2008-01-03

申请号：CA2659762

申请日：2007-06-27

Applicant: ABBOTT LAB

Inventor： GOPALAKRISHNAN SUJATHA ,  EL KOUHEN RACHID ,  SARRIS KATHY A ,  LI JINHE ,  MALYSZ JOHN ,  GUBBINS EARL J ,  GOPALAKRISHNAN MURALI ,  WANG YING ,  MICHMERHUIZEN MELISSA J ,  LYNCH CHRISTOPHER L ,  GFESSER GREGORY A ,  FAGHIH RAMIN

IPC: C07D417/04 ,  A61K31/422 ,  A61K31/427 ,  C07D413/04 ,  C07D417/14

Abstract: The invention relates to compounds of formula I selected from compounds. The compounds of formula (I) in treating conditions and disorders that are r egulated by the nicotinic acetylcholine receptors.